Science Explorer Back to mapMap
Institution · Iscare I.V.F

Most cited papers from Iscare I.V.F

What are the most cited papers from Iscare I.V.F?

The most cited paper from Iscare I.V.F is "European Guidelines for Obesity Management in Adults" (Volkan Demirhan Yumuk, Constantine Tsigos, Martin Fried et al., 2015), with 3,432 citations. Next come "Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial" (931) and "East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort" (432).

Showing 50 of 59 papers. Every paper with more than 34 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 European Guidelines for Obesity Management in Adults Volkan Demirhan Yumuk, Constantine Tsigos, Martin Fried et al. · Obesity Facts Open access 2015 3,432
2 Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial Jean‐Frédéric Colombel et al. · The Lancet 30 Oct 2017 931
3 East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort Johan M. Burisch et al. · Gut Open access 20 Apr 2013 432
4 Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study Johan M. Burisch et al. · Gut Open access 23 Jan 2018 297
5 DNA methylation pattern in human zygotes and developing embryos J. Fulka, Milan Mrazek, Olga Tepla et al. · Reproduction Dec 2004 224
6 The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission Johan M. Burisch et al. · ˜The œLancet. Gastroenterology & hepatology Open access 2 Mar 2023 205
7 Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature Dana Ďuricová, Johan M. Burisch, Tine Jess et al. · Journal of Crohn s and Colitis 18 Jun 2014 192
8 Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group Bo Shen et al. · ˜The œLancet. Gastroenterology & hepatology Open access 16 Jan 2020 181
9 Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006 A. Bortoli, N Pedersen, Dana Ďuricová et al. · Alimentary Pharmacology & Therapeutics 4 Aug 2011 181
10 Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial Walter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch et al. · Gut Open access 13 May 2010 175
11 Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study Johan M. Burisch et al. · ˜The œLancet. Gastroenterology & hepatology Open access 13 Feb 2020 167
12 Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study Johan M. Burisch et al. · Journal of Crohn s and Colitis Open access 2 Oct 2018 166
13 Geographic and age variations in mutational processes in colorectal cancer Marcos Díaz‐Gay et al. · Nature Open access 23 Apr 2025 162
14 Bile acid malabsorption in inflammatory bowel disease Martin Leníček, Dana Ďuricová, Viktor Komárek et al. · Inflammatory Bowel Diseases 7 Nov 2010 130
15 Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial Silvio Danese et al. · ˜The œLancet. Gastroenterology & hepatology Open access101 authors Feb 2022 129
16 Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO Vito Annese, Dana Ďuricová, Corinne Gower‐Rousseau et al. · Journal of Crohn s and Colitis 31 Oct 2015 116
17 Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort Zsuzsanna Végh et al. · Journal of Crohn s and Colitis Open access 3 Jul 2014 107
18 eHealth: individualisation of infliximab treatment and disease course via a self‐managed web‐based solution in C rohn's disease Natalia Pedersen, Margarita Elkjær, Dana Ďuricová et al. · Alimentary Pharmacology & Therapeutics 12 Sep 2012 102
19 Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn’s Disease Torsten F. Kucharzik et al. · Clinical Gastroenterology and Hepatology Open access 13 Jul 2022 101
20 Impact of Anti–Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children Martin Bortlík, Dana Ďuricová, Naděžda Machková et al. · Inflammatory Bowel Diseases 9 Jan 2014 99
21 Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study Silvio Danese et al. · ˜The œLancet. Gastroenterology & hepatology Open access254 authors 17 Nov 2021 96
22 eHealth Natalia Pedersen, Peter Thielsen, Lars Martinsen et al. · Inflammatory Bowel Diseases Open access 23 Sep 2014 93
23 Laparoscopic Sleeve Gastrectomy without an Over-Sewing of the Staple Line Mojmir Kasalicky, David Michalský, Jitka Housova et al. · Obesity Surgery 22 Jul 2008 92
24 Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation Dana Ďuricová, Eva Dvořáková, Ondřej Hradský et al. · Inflammatory Bowel Diseases 20 Sep 2018 84
25 Sur la Notion de Projectivité Solomon Marcus · Mathematical logic quarterly 1965 83
26 Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis Klaudia Farkas et al. · Journal of Crohn s and Colitis Open access 21 Apr 2016 82
27 The natural history of Crohn’s disease in children: a review of population-based studies Dana Ďuricová, Mathurin Fumery, Vito Annese et al. · European Journal of Gastroenterology & Hepatology 30 Sep 2016 81
28 Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers Karin Malíčková, Irena Francová, Milan Lukáš et al. · Practical Laboratory Medicine Open access 23 Sep 2017 79
29 Longitudinal Changes in Body Composition in Patients After Initiation of Hemodialysis Therapy: Results From an International Cohort Daniele Marcelli, Katharina Brand, Pedro Ponce et al. · Journal of Renal Nutrition Open access 28 Nov 2015 74
30 Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis Raja Narayana Atreya, Stuart L Bloom, Franco Scaldaferri et al. · Journal of Crohn s and Colitis Open access 20 May 2016 73
31 Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study Martin Bortlík, Naděžda Machková, Dana Ďuricová et al. · Scandinavian Journal of Gastroenterology 8 Jul 2013 72
32 Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry Kseniya Dryahina, Patrik Španěl, Veronika Pospíšilová et al. · Rapid Communications in Mass Spectrometry 29 Jul 2013 71
33 Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group Bo Shen et al. · ˜The œLancet. Gastroenterology & hepatology 19 Apr 2021 69
34 IBD patients need in health quality of care ECCO consensus Margarita Elkjær, Gabrielle Moser, Walter Reinisch et al. · Journal of Crohn s and Colitis Open access 10 Apr 2008 69
35 Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study Henit A. Yanai et al. · Journal of Crohn s and Colitis Open access 27 Jul 2022 66
36 Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn’s disease and ulcerative colitis Kseniya Dryahina, David Cecil Smith, Martin Bortlík et al. · Journal of Breath Research 7 Aug 2017 63
37 Impaired Deoxyribonuclease I Activity in Patients with Inflammatory Bowel Diseases Karin Malíčková, Dana Ďuricová, Martin Bortlík et al. · Autoimmune Diseases Open access 2011 61
38 Failure of oocyte maturation: Possible mechanisms for oocyte maturation arrest Milan Mrazek · Human Reproduction 30 Oct 2003 60
39 Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Laurent Peyrin‐Biroulet, Perttu E. T. Arkkila, Alessandro Armuzzi et al. · BMC Gastroenterology ReviewOpen access 8 Jun 2022 58
40 Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial Jan Březina, Lukáš Bajer, Pavel Wohl et al. · Journal of Clinical Medicine Open access 22 Jun 2021 55
41 Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? L. Frolová, Karel Smetana, Dana Borovská et al. · Inflammation Research 6 Mar 2009 55
42 Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre Martin Lukáš, Martin Lukas, K Malickova et al. · Journal of Crohn s and Colitis Open access 4 Jan 2020 54
43 Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation Martin Bortlík, Dana Ďuricová, Naděžda Machková et al. · Scandinavian Journal of Gastroenterology 2 Sep 2015 54
44 Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease Marin J. de Jong, Danielle Roosen, Juliette H. R. J. Degens et al. · Journal of Crohn s and Colitis 22 Nov 2018 51
45 Retinol-binding protein 4 expression in visceral and subcutaneous fat in human obesity Magda Bajzová, Michaela Kováčiková, M. Vítková et al. · Physiological Research Open access 2008 50
46 [Inter-disciplinary European guidelines on surgery of severe obesity]. Martin Fried, Vojtěch Hainer, Arnaud Basdevant et al. · PubMed Apr 2008 49
47 Safety of Ustekinumab and Vedolizumab During Pregnancy—Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study Katarína Mitrová, Barbora Pipek, Martin Bortlík et al. · Journal of Crohn s and Colitis 16 Jun 2022 48
48 Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre M. Kolar, Dana Ďuricová, Martin Bortlík et al. · Digestive Diseases 2017 48
49 Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn’s Disease Benjamin Pariente et al. · Gastroenterology Open access 28 May 2021 47
50 Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies Renske W. M. Pauwels et al. · Clinical Gastroenterology and Hepatology ReviewOpen access 30 Apr 2021 42

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.